For research use only. Not for therapeutic Use.
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD)[1].
UCM-1306 (2-(Fluoromethoxy)-4′-(S-methylsulfonimidoyl)-1,1′-biphenyl; 1-10 μM) increases cAMP in a concentration-response manner with high potency (EC50=60 nM).
UCM-1306 (2-(Fluoromethoxy)-4′-(S-methylsulfonimidoyl)-1,1′-biphenyl; 5 mg/kg; p.o.; C57BL/6J mice) has good brain penetration and oral availability. Plasma concentration can be quantified for up to 8 h with Tmax at 0.5 h[1].
UCM-1306 (1 mg/kg; ip) enhances cocaine-induced hyperlocomotion in adult mice[1].
UCM-1306 (1 mg/kg; ip) helps consolidate long-term memory formation[1].
| Catalog Number | I041756 |
| CAS Number | 2258608-78-3 |
| Synonyms | [4-[2-(fluoromethoxy)phenyl]phenyl]-imino-methyl-oxo-λ6-sulfane |
| Molecular Formula | C14H14FNO2S |
| Purity | ≥95% |
| InChI | InChI=1S/C14H14FNO2S/c1-19(16,17)12-8-6-11(7-9-12)13-4-2-3-5-14(13)18-10-15/h2-9,16H,10H2,1H3 |
| InChIKey | VCSBOASGFYJGGT-UHFFFAOYSA-N |
| SMILES | CS(=N)(=O)C1=CC=C(C=C1)C2=CC=CC=C2OCF |
| Reference | [1]. García-Cárceles J, et, al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. J Med Chem. 2022 Sep 22;65(18):12256-12272. |
